Off-Label Uses of Rituximab in Dermatology.

IF 2.4 Q2 DERMATOLOGY Current Dermatology Reports Pub Date : 2022-01-01 DOI:10.1007/s13671-022-00375-4

Connor Cole, Kyle T Amber

引用次数: 1

Abstract

Purpose of review: Rituximab has transformed the treatment of B-cell malignancies and rheumatoid arthritis in the past 2 decades. More recently, this anti-CD20 monoclonal antibody has seen increasing usage in the field of dermatology. This review highlights the evidence supporting its use in several important dermatologic conditions.

Recent findings: Key recent findings include the 2018 FDA approval of rituximab for the treatment of moderate-to-severe pemphigus.

Summary: Data from randomized controlled trials have demonstrated the efficacy of rituximab in pemphigus, ANCA-associated vasculitis, and cryoglobulinemic vasculitis. More limited data suggests its use in recalcitrant cases of diseases such as pemphigoid, epidermolysis bullosa acquisita, and dermatomyositis. There is scarce evidence and mixed results for rituximab when studied in cutaneous polyarteritis nodosa and cutaneous lupus erythematosus.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

利妥昔单抗在皮肤病学中的超说明书使用。

回顾目的:在过去的20年里，利妥昔单抗已经改变了b细胞恶性肿瘤和类风湿关节炎的治疗。最近，这种抗cd20单克隆抗体在皮肤病学领域的应用越来越广泛。本综述强调了支持其在几种重要皮肤病中使用的证据。最近的主要发现包括2018年FDA批准利妥昔单抗治疗中重度天疱疮。摘要:来自随机对照试验的数据已经证明了美罗华治疗天疱疮、anca相关血管炎和冷球蛋白性血管炎的疗效。更有限的数据表明，它用于顽固性疾病，如类天疱疮、获得性大疱性表皮松解症和皮肌炎。当研究皮肤结节性多动脉炎和皮肤红斑狼疮时，利妥昔单抗缺乏证据和混合结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Dermatology Reports DERMATOLOGY-

CiteScore

3.30

自引率

6.20%

发文量

期刊介绍： This journal intends to review the most significant recent developments in the field of dermatology. By providing clear, insightful, balanced contributions by expert international authors, the journal aims to serve all those involved in the diagnosis, treatment, management, and prevention of dermatologic conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas across the field, such as epidemiology, surgery, pharmacology, clinical trial design, and pediatrics. Section Editors select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known figures in the field, and an Editorial Board of more than 20 internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.

期刊最新文献

Skin Type Diversity in Skin Lesion Datasets: A Review. Teledermatology Lessons During the COVID-19 Pandemic Mpox: Diagnosis and Management for the Inpatient Dermatologist Inpatient Evaluation and Management of Generalized Pustular Dermatoses Immune Checkpoint Inhibitors and Systemic Side Effects: Overview for the Inpatient Dermatologist